Point of Care Infectious Disease Testing Market Report

Infectious disease are also known transmissible disease or communicable disease. The disease is mostly caused due to pathogenic micro-organisms and can be transmitted between individuals and populations. The diagnosis of infectious disease plays a key role for the identifying the infectious agent.  Point of care infectious disease testing helps to diagnose the patient and further proceed for treatment based on results.  The testing reduces the need for multiple patient visits and also enable timely treatment as well as facilitate to initiate precise treatment for patient. The increasing number of different disease and growing number of patient had led the demand for point of care infectious disease testing market.

Point of Care Infectious Disease Testing Market Report Outlook

The global point of care infectious disease testing market is driven by the high demand for portable and rapid testing devices as the point of care device portable device can performed blood analysis which further enables the physician to make treatment decision while diagnosing. Further the portable and rapid testing devices offers benefits for patient to get test done by bedside with instant diagnostic results. Also, emerging nations to offer new growth avenues is boosting the market growth due to increasing adoption worldwide in hospitals, diagnostic laboratories and home-care settings. Besides rising incidences & prevalence rates of communicable diseases has led the huge demand point of care infectious disease testing market. For instance according to WHO, it was estimated that 38.0 million people are living with HIV which further provides an opportunity for the growth of global point of care infectious disease testing market

COVID 19 IMPACT ON POINT OF CARE INFECTIOUS DISEASE TESTING MARKET REPORT

The exclusive COVID 19 impact analysis report by Axiom MRC provides a 3600 analysis of micro and macro-economic factors on the point of care infectious disease testing market. In addition, complete analysis of changes on the point of care infectious disease testing market expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on global economies, international trade, business investments, GDP and marketing strategies of key players present in the market.  

POINT OF CARE INFECTIOUS DISEASE TESTING MARKET SEGMENTAL OVERVIEW

The point of care infectious disease testing market is segmented based on disease, application, end user and geography. 

POINT OF CARE INFECTIOUS DISEASE TESTING MARKET BY DISEASE 

The point of care infectious disease testing is available in market for various disease like hiv poc, clostridium difficile poc, hbv poc, hcv poc, hpv poc, hsv (herpes simplex virus) poc, influenza/flu poc, mrsa poc, pneumonia or streptococcus associated infections, respiratory syncytial virus (rsv) poc, tb and drug-resistant tb poc. HIV POC is estimated to dominate in the global point of care infectious disease testing market due to increasing testing which allows the patient to tested for HIV and receive results at the same time.  Besides, the testing helps for HIV that have unprocessed specimens which are able to detect HIV infections with high specificity and sensitivity

POINT OF CARE INFECTIOUS DISEASE TESTING MARKET BY APPLICATION  

The point of care infectious disease testing finds application in during pregnancy, outside pregnancy. During pregnancy is projected to lead in the global point of care infectious disease testing market. The market. The testing ideally has the potential to enhance strategies to prevent mother to child transmission of HIV infections. Also, the rapid testing help to minimize the laboratory infrastructure and can be performed by health workers  

POINT OF CARE INFECTIOUS DISEASE TESTING MARKET BY END USE

The point of care infectious disease testing market has end use in hospitals, diagnostic laboratories, and home-care settings. Hospitals is anticipated to gain major market in point of care infectious disease testing market. The increasing use point of care infectious disease testing as the testing is simple medical test which can be performed at the beside of patient. It provides an easy way for the physicians as well as patient to conduct test and helps physicians for patient management 

POINT OF CARE INFECTIOUS DISEASE TESTING MARKET BY GEOGRAPHY

Geographically point of care infectious disease testing market is studied for the following region North America, Europe, Asia Pacific and RoW.  North America is anticipated to dominate in the global Point of Care Infectious Disease Testing market owing to increasing demand for the market from the various end use industry. Besides the developed healthcare infrastructure and adoption of point of care infectious disease testing is propelling the growth of the market. Also, presence of key players in region and growing activities of merger & acquisition, new launch & product innovation is further fueling the demand for the market. Technological advancement and adoption is the key factor boosting the region growth. Furthermore, Asia Pacific is projected to witness the growth at highest pace during the forecast period. The growing number of patient for different disease is accelerating the demand for point of care infectious disease testing market. In addition presence of key countries like China, India and Japan is fueling the demand of market and increasing R & D activities is driving the market growth. 

POINT OF CARE INFECTIOUS DISEASE TESTING MARKET KEY PLAYER

The key players in point of care infectious disease testing market are Beckman Coulter, Inc., Abbott Laboratories, Becton Dickinson Company, bioMérieux SA, Bio-Rad Laboratories, Inc., Cardinal Health, Cepheid, Chembio Diagnostics Systems, Inc, Danaher, Gene POC, Hoffmann-La Roche Ltd, OJ-Bio Ltd, Ortho Clinical Diagnostics, Quest Diagnostics Inc., Siemens Healthineers, Sight Diagnostics Ltd, Thermo Fisher Scientific, Inc., Trinity Biotech and Trivitron Healthcare among others.  

POINT OF CARE INFECTIOUS DISEASE TESTING MARKET RECENT DEVELOPMENT

March 2020:  Abbott had launched the molecular point of care test to detect Novel Corona virus in as little as five minutes.  The test will run on the company’s ID Now platform, providing rapid results in a wide range of healthcare setting such as physician office, urgent care clinics, and hospital emergency department.